# Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia

> **NCT01327014** · PHASE2 · COMPLETED · sponsor: **Beijing Peking University WBL Biotech Co., Ltd.** · enrollment: 116 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** XueZhiKang (XZK), a botanic product with multiple components
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01327014
- **Lead sponsor:** Beijing Peking University WBL Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2014-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01327014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01327014, "Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01327014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*